Defining Process Design Space for Monoclonal Antibody Cell Culture

被引:87
作者
Abu-Absi, Susan Fugett [1 ]
Yang, LiYing [1 ]
Thompson, Patrick [1 ]
Jiang, Canping [1 ]
Kandula, Sunitha [1 ]
Schilling, Bernhard [1 ]
Shukla, Abhinav A. [1 ]
机构
[1] Bristol Myers Squibb Co, Mfg Sci & Technol, E Syracuse, NY 13057 USA
关键词
cell culture; design space; quality by design; monoclonal antibody; GLYCOSYLATION; QUALITY; CHROMATOGRAPHY; PROTEIN;
D O I
10.1002/bit.22764
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The concept of design space has been taking root as a foundation of in-process control strategies for biopharmaceutical manufacturing processes. During mapping of the process design space, the multidimensional combination of operational variables is studied to quantify the impact on process performance in terms of productivity and product quality. An efficient methodology to map the design space for a monoclonal antibody cell culture process is described. A failure modes and effects analysis (FMEA) was used as the basis for the process characterization exercise. This was followed by an integrated study of the inoculum stage of the process which includes progressive shake flask and seed bioreactor steps. The operating conditions for the seed bioreactor were studied in an integrated fashion with the production bioreactor using a two stage design of experiments (DOE) methodology to enable optimization of operating conditions. A two level Resolution IV design was followed by a central composite design (CCD). These experiments enabled identification of the edge of failure and classification of the operational parameters as non-key, key or critical. In addition, the models generated from the data provide further insight into balancing productivity of the cell culture process with product quality considerations. Finally, process and product-related impurity clearance was evaluated by studies linking the upstream process with downstream purification. Production bioreactor parameters that directly influence antibody charge variants and glycosylation in CHO systems were identified. Biotechnol. Bioeng. 2010;106: 894-905. (C) 2010 Wiley Periodicals, Inc.
引用
收藏
页码:894 / 905
页数:12
相关论文
共 23 条
[1]   Effect of Culture Temperature on Erythropoietin Production and Glycosylation in a Perfusion Culture of Recombinant CHO Cells [J].
Ahn, Woo Suk ;
Jeon, Jae-Jin ;
Jeong, Yeong-Ran ;
Lee, Seung Joo ;
Yoon, Sung Kwan .
BIOTECHNOLOGY AND BIOENGINEERING, 2008, 101 (06) :1234-1244
[2]  
Andersen DC, 2000, BIOTECHNOL BIOENG, V70, P25, DOI 10.1002/1097-0290(20001005)70:1<25::AID-BIT4>3.0.CO
[3]  
2-Q
[4]  
[Anonymous], 2006, GUID IND Q8 PHARM DE
[5]   Identification of Cell Culture Conditions to Control N-Glycosylation Site-Occupancy of Recombinant Glycoproteins Expressed in CHO Cells [J].
Gawlitzek, Martin ;
Estacio, Michael ;
Fuerch, Tobias ;
Kiss, Robert .
BIOTECHNOLOGY AND BIOENGINEERING, 2009, 103 (06) :1164-1175
[6]   Defining process design space for biotech products:: Case study of Pichia pastoris fermentation [J].
Harms, Jean ;
Wang, Xiangyang ;
Kim, Tina ;
Yang, Xiaoming ;
Rathore, Anurag S. .
BIOTECHNOLOGY PROGRESS, 2008, 24 (03) :655-662
[7]   Glycosylation of recombinant antibody therapeutics [J].
Jefferis, R .
BIOTECHNOLOGY PROGRESS, 2005, 21 (01) :11-16
[8]  
KELLEY B, 1998, VALIDATION BIOPHARMA, P93
[9]  
Kelley BD, 1997, BIOPHARM-TECHNOL BUS, V10, P36
[10]   Current and future issues in the manufacturing and development of monoclonal antibodies [J].
Kozlowski, Steven ;
Swann, Patrick .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (5-6) :707-722